Talha Badar/X
Jan 22, 2025, 20:37
Talha Badar: Focusing on “chemo-free” regimen for “Ph-ve” B-cell ALL
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X:
“Focusing on ‘chemo-free’ regimen for ‘Ph-ve’ B-cell ALL.
- Blinatumomab is better induction or Inotuzumab ozogamicin?
- Response rate with the chemo-free regimen in high-risk ALL?
- Should we intensify CNS prophylaxis with a “chemo-free” regimen?
SWOG 1318: PII study of Blina (inductionà 3 consolidation cycles) followed by POMP (Advani et al JCO 2022):
- Patients 65 years or older (N=29)
- 34% poor risk CG, median BM blast 87%
- 66% CR rate
- 3 years DFS and OS 37%
InO induction followed by age-adapted chemotherapy (INITIAL -1) (Stelljes et al. JCO 2023).
The GMALL group conducted a PII trial exploring InO (up to 2 cycles) + Dex induction followed by age-adapted chemotherapy in elderly ALL:
- 43 patients, median age 64 years (R, 58-80)
- 100% CR (71% MRD negative)
- 3 years EFS and OS 55% and 73%
Inotuzumab followed by Blinatumomab induction in elderly patients, Alliance A041703 (Wieduwilt et al. ASCO 2023):
- 31 patients treatment, CR 85% after Inotuzumab, 97% after Blina
- Median follow-up 22 months; 1 years EFS 75%, OS 84%
Summary:
- Inotuzumab is a better induction/upfront strategy than blinatumomab.
- ‘Chemo-free’ regimen might not be as effective in high-risk ALL patients.
- May need to intensify CNS prophylaxis, using ‘chemo-free’ regimens.”
More posts featuring Talha Badar.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 22, 2025, 20:37
Jan 22, 2025, 18:49
Jan 22, 2025, 16:52
Jan 22, 2025, 16:21
Jan 22, 2025, 16:20
Jan 22, 2025, 16:17